Your browser doesn't support javascript.
loading
CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis.
Marastoni, Damiano; Magliozzi, Roberta; Bolzan, Anna; Pisani, Anna Isabella; Rossi, Stefania; Crescenzo, Francesco; Montemezzi, Stefania; Pizzini, Francesca Benedetta; Calabrese, Massimiliano.
Afiliación
  • Marastoni D; From the Department of Neurosciences (D.M., R.M., A.B., A.I.P., F.C., M.C.), Biomedicine and Movement Sciences, University of Verona; Department of Brain Sciences (R.M.), Imperial College London, Hammersmith Hospital, UK; Department of Oncology and Molecular Medicine (S.R.), Higher Institute of Heal
  • Magliozzi R; From the Department of Neurosciences (D.M., R.M., A.B., A.I.P., F.C., M.C.), Biomedicine and Movement Sciences, University of Verona; Department of Brain Sciences (R.M.), Imperial College London, Hammersmith Hospital, UK; Department of Oncology and Molecular Medicine (S.R.), Higher Institute of Heal
  • Bolzan A; From the Department of Neurosciences (D.M., R.M., A.B., A.I.P., F.C., M.C.), Biomedicine and Movement Sciences, University of Verona; Department of Brain Sciences (R.M.), Imperial College London, Hammersmith Hospital, UK; Department of Oncology and Molecular Medicine (S.R.), Higher Institute of Heal
  • Pisani AI; From the Department of Neurosciences (D.M., R.M., A.B., A.I.P., F.C., M.C.), Biomedicine and Movement Sciences, University of Verona; Department of Brain Sciences (R.M.), Imperial College London, Hammersmith Hospital, UK; Department of Oncology and Molecular Medicine (S.R.), Higher Institute of Heal
  • Rossi S; From the Department of Neurosciences (D.M., R.M., A.B., A.I.P., F.C., M.C.), Biomedicine and Movement Sciences, University of Verona; Department of Brain Sciences (R.M.), Imperial College London, Hammersmith Hospital, UK; Department of Oncology and Molecular Medicine (S.R.), Higher Institute of Heal
  • Crescenzo F; From the Department of Neurosciences (D.M., R.M., A.B., A.I.P., F.C., M.C.), Biomedicine and Movement Sciences, University of Verona; Department of Brain Sciences (R.M.), Imperial College London, Hammersmith Hospital, UK; Department of Oncology and Molecular Medicine (S.R.), Higher Institute of Heal
  • Montemezzi S; From the Department of Neurosciences (D.M., R.M., A.B., A.I.P., F.C., M.C.), Biomedicine and Movement Sciences, University of Verona; Department of Brain Sciences (R.M.), Imperial College London, Hammersmith Hospital, UK; Department of Oncology and Molecular Medicine (S.R.), Higher Institute of Heal
  • Pizzini FB; From the Department of Neurosciences (D.M., R.M., A.B., A.I.P., F.C., M.C.), Biomedicine and Movement Sciences, University of Verona; Department of Brain Sciences (R.M.), Imperial College London, Hammersmith Hospital, UK; Department of Oncology and Molecular Medicine (S.R.), Higher Institute of Heal
  • Calabrese M; From the Department of Neurosciences (D.M., R.M., A.B., A.I.P., F.C., M.C.), Biomedicine and Movement Sciences, University of Verona; Department of Brain Sciences (R.M.), Imperial College London, Hammersmith Hospital, UK; Department of Oncology and Molecular Medicine (S.R.), Higher Institute of Heal
Neurol Neuroimmunol Neuroinflamm ; 8(6)2021 11.
Article en En | MEDLINE | ID: mdl-34588298
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Crónica Progresiva / Esclerosis Múltiple Recurrente-Remitente / Osteopontina / Quimiocina CXCL12 Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Neurol Neuroimmunol Neuroinflamm Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Crónica Progresiva / Esclerosis Múltiple Recurrente-Remitente / Osteopontina / Quimiocina CXCL12 Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Neurol Neuroimmunol Neuroinflamm Año: 2021 Tipo del documento: Article